Clinical trials: Schizophrenia Therapeutics
- Condition Schizophrenia Therapeutics
- Funder type Industry (pharma, biotech, devices)
- Age group Children (under 18)
Schizophrenia, Bipolar Disorder
Aripiprazole Open-Label, Safety and Tolerability Study
The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.
- Trial name
- APEX 241 (NCT00102518)
- Testing
- Aripiprazole
- Where
- 50 sites in United States
- Volunteers
- 325 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Schizophrenia
A Study to Test if TV-46000 is Safe for Maintenance Treatment of Schizophrenia
The primary objective of the study is to evaluate the long-term safety and tolerability of TV-46000. The primary safety and tolerability endpoint is the frequency of all adverse events, including serious adverse events.
- Trial name
- SHINE (NCT03893825)
- Testing
- TV-46000
- Where
- 90 sites in United States, Bulgaria and 3 more
- Volunteers
- 336 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Hallucinations, Psychoses
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
The primary objective is to demonstrate that the investigational new drug, ACP-103, is well tolerated by, and will not worsen parkinsonism in, patients with Parkinson's disease and psychosis.
- Conditions
- Hallucinations, Psychoses, Parkinson's Disease
- Trial name
- NCT00087542
- Testing
- ACP-103
- Where
- 13 sites in United States
- Volunteers
- 60 people
- Sponsor
- ACADIA Pharmaceuticals Inc.
Schizophrenia
The Safety and Effectiveness of Latuda® Post-marketing Surveillance in the Treatment of Chinese Schizophrenia Patients
It's a prospective, non-interventional, observational Post-marketing Surveillance..
- Trial name
- NCT04432688
- Testing
- Lurasidone HCl
- Where
- 7 sites in China
- Volunteers
- 3,192 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Bipolar Disorder, Affective Disorders, Psychotic
A Study to Evaluate the Safety and Effectiveness of Topiramate Compared to Placebo in the Treatment of Patients With Bipolar I Disorder
The purpose of this study is to determine the safety and efficacy of topiramate in adolescents with manic or mixed episodes of Bipolar I Disorder.
- Conditions
- Bipolar Disorder, Affective Disorders, Psychotic, Mood Disorders, Mental Disorders
- Trial name
- NCT00035802
- Testing
- Topiramate
- Volunteers
- 13 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Psychotic Disorders
CAFE Comparison of Atypicals in First Episode of Psychosis
The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day)…
- Conditions
- Schizophrenia, Psychotic Disorders, Mental Health, Mental Disorders
- Trial name
- NCT00034892
- Testing
- Olanzapine, risperidone
- Where
- 26 sites in United States, Canada
- Sponsor
- AstraZeneca
Schizophrenia
Adaptive Phase II Study to Evaluate the Safety & Efficacy of NaBen®
The purpose of this study is to determine if NaBen® is a safe and effective add-on treatment for schizophrenia in adolescents.
- Trial name
- NCT01908192
- Testing
- NaBen®
- Where
- 23 sites in United States, Taiwan
- Volunteers
- 60 people
- Sponsor
- SyneuRx International (Taiwan) Corp
Alzheimer's Disease, Dementia
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Patients With Hallucinations and Delusions Associated With Alzheimer's Disease
The purpose of this study is to assess the effectiveness and safety of risperidone (an antipsychotic medication) versus placebo for the treatment of patients with hallucinations and delusions associated with Alzheimer's disease.
- Trial name
- NCT00287742
- Testing
- risperidone
- Volunteers
- 33 people
- Sponsor
- Janssen Pharmaceutical K.K.
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Fixed Dose Efficacy and Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05896)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is also effective in adolescents with…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190254
- Testing
- asenapine 2.5 mg, asenapine 5.0 mg
- Volunteers
- 306 people
- Sponsor
- Organon and Co
Schizophrenia
Study to Evaluate TV-46000 as Maintenance Treatment in Adult and Adolescent Participants With Schizophrenia
The purpose of the study is to evaluate the efficacy, safety, and tolerability of different dose regimens of TV-46000 administered subcutaneously (SC) as compared to placebo during maintenance treatment in adult and adolescent…
- Trial name
- RISE (NCT03503318)
- Testing
- TV-46000
- Where
- 81 sites in United States, Bulgaria
- Volunteers
- 544 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Schizophrenia
Olanzapine Versus Placebo in the Treatment of Adolescents With Schizophrenia
This study is to determine the efficacy (how well the drug works), safety, and any side effects of olanzapine compared to placebo in the treatment of schizophrenia in adolescents.
- Trial name
- NCT00051298
- Testing
- Olanzapine
- Where
- 25 sites in United States, Russia
- Volunteers
- 107 people
- Sponsor
- Eli Lilly and Company
Schizophrenia, Autism-Related Irritability
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
The purpose of this study is to evaluate the long-term safety and tolerability of Xanomeline and Trospium Chloride for the treatment of psychiatric disorders in children and adolescents
- Trial name
- NCT07424404
- Testing
- KarXT, KarX-EC
- Where
- 105 sites in United States, Australia and 9 more
- Volunteers
- 400 people
- Sponsor
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Schizophrenia
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.
- Trial name
- NCT03817502
- Testing
- Cariprazine
- Where
- 57 sites in United States, Bulgaria and 6 more
- Volunteers
- 330 people
- Sponsor
- Gedeon Richter Plc.
Bipolar Disorders, Mood Disorders
A Study of the Effectiveness and Safety of Topiramate in the Treatment of Patients With Bipolar Disorder
The primary purpose of this study is to evaluate the effectiveness and safety of topiramate compared with placebo in the treatment of acute manic or mixed episodes in patients with Bipolar I Disorder.
- Conditions
- Bipolar Disorders, Mood Disorders, Affective Disorders, Psychotic
- Trial name
- NCT00240721
- Testing
- topiramate
- Volunteers
- 363 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Paranoid, Schizophrenia, Disorganized
Flexible Dose, Long-term Safety Study of Asenapine for the Treatment of Schizophrenia in Adolescents (P05897)
This study is designed to evaluate whether asenapine, which is approved by the United States Food and Drug Administration (US FDA) for acute treatment of schizophrenia in adults, is generally safe and well tolerated in…
- Conditions
- Schizophrenia, Paranoid, Schizophrenia, Disorganized, Schizophrenia, Undifferentiated
- Trial name
- NCT01190267
- Testing
- asenapine
- Volunteers
- 204 people
- Sponsor
- Organon and Co
Schizophrenia
A Short Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the efficacy and safety of three different doses of aripiprazole (2 mg/day, 6-12 mg/day, 24-30 mg/day) orally administered over a period of 6 weeks in pediatric patients (aged 13-17…
- Trial name
- NCT01942161
- Testing
- Aripiprazole Low (2 mg/day), Aripiprazole Mid (6 - 12 mg/day), Aripiprazole High (24 - 30 mg/day)
- Where
- 8 sites in Japan
- Volunteers
- 106 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
The purpose of this study is to evaluate the efficacy and safety of extended-release (ER) paliperidone compared to aripiprazole (atypical antipsychotic) in symptomatic (having symptoms) adolescent participants with schizophrenia…
- Trial name
- NCT01009047
- Testing
- Paliperidone extended release (ER), Aripiprazole
- Where
- 41 sites in United States, India and 5 more
- Volunteers
- 228 people
- Sponsor
- Janssen Research & Development, LLC
Schizophrenia
A Long-term, Extended Treatment Study of Aripiprazole in Pediatric Patients With Schizophrenia
The objective of this study is to investigate the safety and efficacy of aripiprazole (initial dose 2 mg/day, maintenance dose 6-24 mg/day, maximum dose 30 mg/day) orally administered over a period of 52 weeks in subjects who…
- Trial name
- NCT01942148
- Testing
- Aripiprazole
- Where
- 8 sites in Japan
- Volunteers
- 68 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Schizophrenia
Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia
The purpose of this study is to demonstrate efficacy and safety of quetiapine fumarate (SEROQUEL) compared with placebo in the treatment of adolescent patients with schizophrenia.
- Trial name
- ANCHOR 112 (NCT00090324)
- Testing
- quetiapine fumarate tablets
- Where
- 42 sites in United States, Germany and 8 more
- Volunteers
- 249 people
- Sponsor
- AstraZeneca
Schizophrenia
Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia
This primary objective for this study is to evaluate the effect of adjunctive valbenazine versus placebo on symptoms of schizophrenia in participants who have inadequate response to antipsychotic treatment.
- Trial name
- NCT05654870
- Testing
- Valbenazine
- Where
- 3 sites in United States
- Volunteers
- 8 people
- Sponsor
- Neurocrine Biosciences